Acrivon Therapeutics, Inc. (ACRV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Silvan Tuerkcan from JMP Securities maintained a Buy rating on the stock and has a $17.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Silvan Tuerkcan’s rating is based on Acrivon Therapeutics’ promising clinical developments and strategic positioning in the oncology field. The company is advancing two clinical-stage assets, ACR-368 and ACR-2316, through its AP3 platform, which shows potential in treating advanced cancers. ACR-368, particularly in advanced/recurrent endometrial cancer, has demonstrated a high objective response rate (ORR) of 63% in biomarker-selected patients, surpassing the standard of care. This strong efficacy profile supports the potential for accelerated approval and movement into the frontline setting.
Additionally, the company’s focus on phosphoproteomics-based data introduces a novel approach in oncology, enhancing its competitive edge. The upcoming R&D event, featuring key opinion leaders, is expected to provide further insights into ACR-368’s positioning and the progress of ACR-2316. These factors collectively underpin Tuerkcan’s confidence in Acrivon’s growth prospects, justifying the Buy rating.